Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582158 | 0.79 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1KDM4E | |
| SCHEMBL2583741 | 0.78 | SIGMAR1 (0.54) | ALDH1A1POLBRAB9AHTTLMNA | |
| SCHEMBL24709607 | 0.77 | ALDH1A1 (0.67) | ALDH1A1POLBRAB9AHTTLMNA | |
| Bromide SCHEMBL31141385 | 0.76 | ALDH1A1 (0.65) | ALDH1A1POLBRAB9AHTTLMNA | |
| SCHEMBL2580263 | 0.75 | SMN1; SMN2 (0.56) | POLBRAB9AHTTLMNASMN1; SMN2 | |
| SCHEMBL8117468 | 0.73 | MAPT (0.67) | MAPTKDM4E | |
| SCHEMBL28801601 | 0.72 | ALDH1A1 (0.61) | ALDH1A1POLBRAB9AHTTLMNA | |
| SCHEMBL2581178 | 0.72 | ALDH1A1 (0.62) | ALDH1A1RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL2582523 | 0.72 | ALDH1A1 (0.57) | ALDH1A1RAB9AHTTNPC1KDM4E | |
| SCHEMBL31474229 | 0.71 | ALDH1A1 (1.00) | ALDH1A1POLBRAB9AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048877-B2 | Guanidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | claimed |
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | ACESION PHARMA APS (DK) | 2009-04-16 | — | — | US | claimed |
| US-8048877-B2 | Guanidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | disclosed |
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | ACESION PHARMA APS (DK) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNN2, KCNN1, KCNN3 | ALDH1A1 4060/4885POLB 4457/4885RAB9A 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.